Cytosorbents Corporation (CTSO) Stock Price & How to Invest

Last updated November 2026

Short answer

CytoSorbents is a small Princeton, New Jersey medical device company that sells CytoSorb, a blood purification cartridge used in intensive care and cardiac surgery, mostly in Europe. At ~$4.39 on November 20, 2026 (down ~66% this year), the company was valued near ~$14 million against ~$37 million of yearly sales. A financing announced that day cut its Avenue Capital debt from ~$17.5 million to ~$12.25 million and pushed the maturity to July 2028, while a Nasdaq listing deadline remains.

CTSO stock price

As of 2026-11-20, Cytosorbents Corporation (CTSO) last closed at $4.16, down 70.6% over the past year. Over the past 52 weeks it has traded between $3.06 and $16.74.

CTSO last close
$4.16
1 day
-18.91%
1 month
-22.24%
1 year
-70.58%
52-week range
$3.06 to $16.74
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Cytosorbents Corporation's investor relations page. Walnut is informational, not investment advice.

CTSO key stats

At $4.16 on November 20, 2026, Cytosorbents Corporation (CTSO) has a market cap of $13M.

Market cap
$13M

Market cap, P/E and yield are measured at the $4.16 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Cytosorbents Corporation (CTSO)?

The last two weeks for Cytosorbents Corporation, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • CTSO closed at $4.16 on November 20, 2026, down 14.6% over the past five trading days (from $4.87).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Cytosorbents Corporation (CTSO) do?

CytoSorbents makes porous polymer beads packed into cartridges that clip into a blood circuit and pull inflammatory molecules, toxins and some drugs out of a patient's blood. Its main product, CytoSorb, is approved in the European Union and distributed in more than 70 countries, where intensive care units use it in septic shock and cardiac surgeons use it during bypass procedures. The company also owns DrugSorb-ATR, a version aimed at removing the blood thinner Brilinta (ticagrelor) during urgent heart surgery, which is not yet authorized in the United States, and HemoDefend-BGA, an early program meant to make universal plasma. Nearly all revenue comes from outside the U.S.: in the third quarter of 2026 American sales were about $70,000 out of $9.7 million.

The Q3 2026 report, filed November 12 and corrected on November 19, showed revenue up ~3% year over year to ~$9.7 million, with distributor and partner sales up ~18% and German sales down ~21% after a sales force cut. Gross margin rose to ~75% from ~70%. Operating expenses fell ~11% to ~$8.5 million, the operating loss narrowed to ~$1.2 million, and the company reported roughly breakeven operating cash flow excluding restructuring payments. For the nine months, revenue was ~$28.2 million and net loss ~$12.0 million, inflated by a ~$2.5 million non-cash currency loss. The 10-Q was filed late, after a review of how those currency losses were calculated, and management reported continuing material weaknesses in internal controls.

The investment picture is dominated by the balance sheet. At September 30 the company had ~$4.2 million of unrestricted cash plus ~$1.5 million restricted, against ~$17.5 million of Avenue Capital debt that was due to start amortizing after December 31, 2026 and mature July 1, 2027. Stockholders' equity was a deficit of ~$2.3 million and the 10-Q carries a going-concern warning. On November 20, 2026 the company announced a ~$6.25 million package: a ~$4.0 million registered direct offering at $4.94 a share (insiders paid $5.18), about 75% taken up by existing holders, management and the board, plus ~$2.25 million of loan principal repaid in stock to Avenue. Principal fell to ~$12.25 million, interest-only payments now run to March 31, 2028, and maturity moved to July 1, 2028. The stock went through a 1-for-20 reverse split on September 8, 2026 and has traded between ~$2.84 and ~$17.00 (split-adjusted) over the past year. It closed at ~$4.39 on November 20, down ~66.5% year to date and ~64.7% over twelve months, for a market value of ~$14 million on the pre-offering share count, well below the $35 million Nasdaq requires, with a compliance deadline of December 28, 2026.

What's driving Cytosorbents Corporation (CTSO)?

1. Operating cash flow at breakeven

The first goal management set for 2026 was to stop burning cash, and the Q3 numbers say it got there. Q3 net loss of ~$1.83 million, or ~-$0.58 a share, was narrower than the ~-$0.90 analysts expected, the first beat after three quarters of wider-than-forecast losses. Operating cash flow was about +$43,000 excluding ~$251,000 of restructuring payments, against a burn of ~$2.7 million in Q3 2025. Total cash burn including restructuring was ~$200,000. The levers were a ~24% headcount cut since September 2025, cheaper manufacturing that lifted gross margin to ~75%, and inventory reduced from ~$5.3 million at year end to ~$3.2 million. Some of that inventory drawdown is one-time, so the next few quarters will show whether breakeven holds when working capital stops releasing cash and the company begins rehiring sales staff in Germany.

2. Returning CytoSorb to growth

Total revenue has been close to flat for two years, at ~$35.6 million in 2024 and ~$37.1 million in 2025, with nine-month 2026 revenue up only ~1.4%. Inside that, the mix is shifting. Distributor and strategic partner sales, about half of Q3 revenue at ~$5.1 million, grew ~18%, and direct sales outside Germany rose ~5%. Germany, once a third of sales, fell to ~23% of the quarter after territory cuts. The company has added two German representatives, plans three more by early 2027 and hired a new head of direct sales. With ~75% gross margins, every added dollar of sales carries most of its value to the bottom line if expenses stay near ~$8.5 million a quarter.

3. DrugSorb-ATR and the U.S. market

DrugSorb-ATR is the company's route into the United States. The FDA denied the original De Novo application and upheld that denial on appeal in August 2025, citing no safety concerns but asking for more real-world evidence. The company now plans a new submission in early 2027, built on the STAR-T trial (published in the Journal of Thoracic and Cardiovascular Surgery), an independent 587-patient matched analysis showing severe bleeding of ~21.8% with CytoSorb versus ~34.5% without, and an animal study whose protocol still needs FDA sign-off. A second filing for Eliquis and Xarelto removal is planned. Management sizes the initial U.S. and Canadian market at ~$300 million; that figure is the company's estimate, and any decision would follow a review of roughly 150 days.

4. HemoDefend-BGA as a separate asset

HemoDefend-BGA is designed to strip anti-A and anti-B antibodies from plasma and platelets so a single product could be given to patients of any blood type. It was developed with ~$16 million of U.S. government funding and received FDA feedback on a clinical pathway in July 2026. Management says it will look for more grant money, a partner, a license or another strategic deal for the program, so that it does not drain the core business. For a company valued at ~$16 million, any upfront payment from a licensing deal could matter to the balance sheet, though no agreement has been announced and the product is still years from potential approval.

What are the risks to Cytosorbents Corporation (CTSO)?

Financing is still the largest risk, though the November 2026 deal changed its shape. Avenue Capital debt fell from ~$17.5 million to ~$12.25 million, interest-only payments were extended to March 31, 2028 (three more months if DrugSorb-ATR is approved by then) and maturity moved to July 1, 2028; the company puts interest savings at ~$0.7 million over twelve months. Avenue can now convert up to ~$3.0 million of principal at $6.916 a share, and another ~$3.125 million at $8.645 from the earlier of DrugSorb-ATR approval or January 1, 2028, so further dilution is built in. Most of the ~$4.0 million of new cash went to repaying ~$3.0 million of principal plus fees, which leaves the company relying on breakeven operations. Listing is the second risk: the market value is far below Nasdaq's $35 million minimum, the December 28, 2026 deadline is close, and the new shares add equity but the company itself says there is no assurance it keeps the listing. Accounting is a third: material weaknesses persist, and the Q3 10-Q was filed late after a currency loss error; the first release understated nine-month net loss by ~$0.6 million. Regulatory risk remains, because the FDA has already turned down DrugSorb-ATR once, and the business depends heavily on German and European hospital budgets.

Is CTSO a buy or a sell?

We give no verdict on Cytosorbents Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Operating cash flow at breakeven. The first goal management set for 2026 was to stop burning cash, and the Q3 numbers say it got there.

The case against. Financing is still the largest risk, though the November 2026 deal changed its shape.

Read the full bull and bear case on CTSO, including what would have to change to break either one. Walnut is not an investment adviser.

How is Cytosorbents Corporation (CTSO) valued?

Market cap, P/E and dividend yield at today's price are in the CTSO key stats above. The business figures below come from Cytosorbents Corporation's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$37.5 million
  • Revenue growth (Q3 2026, yoy): ~+2.6%
  • Gross margin (TTM): ~73%
  • Net loss (TTM): ~-$16.9 million
  • Avenue debt after Nov 2026 amendment: ~$12.25 million, due July 2028

As of November 2026: At ~$4.39 the stock trades at roughly 0.4 times trailing sales, a level usually seen in medical device companies with serious balance sheet problems. Earnings ratios do not apply: trailing net loss is ~$16.9 million, much of it from non-cash currency swings and interest, and analysts expect a ~-$3.72 per-share loss for 2026. The November 2026 amendment cut the Avenue loan to ~$12.25 million and moved the maturity to July 2028, so the valuation now rests more on whether a business near cash breakeven with ~73-75% gross margins can grow toward the ~$44 million of 2027 revenue analysts forecast.

Who competes with Cytosorbents Corporation (CTSO)?

Blood purification devices

Jafron Biomedical of China sells HA-series hemoadsorption cartridges in large volumes, mainly in China, and Baxter offers the oXiris filter alongside its Prismaflex dialysis systems. Spectral Medical is pursuing U.S. approval of the Toraymyxin endotoxin column. These compete with CytoSorb for the same ICU and cardiac surgery budgets and the same clinical evidence debates.

Blood thinner reversal

DrugSorb-ATR competes with drug-based approaches to bleeding in patients on blood thinners. SERB Pharmaceuticals has developed bentracimab, an antibody meant to reverse ticagrelor, and specific reversal agents exist for some Xa inhibitors. Surgeons can also delay surgery several days for the drug to clear, which is the main alternative today.

Blood products and safety

For HemoDefend-BGA, the relevant players are blood centers and plasma suppliers such as Octapharma, which sells pooled, solvent-detergent treated plasma (Octaplas), and Cerus, whose INTERCEPT system treats plasma and platelets for pathogen safety. Universal low-titer O whole blood programs at trauma centers address a similar need through blood bank practice.

What stocks are similar to Cytosorbents Corporation (CTSO)?

Other names that sit close to CTSO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Cytosorbents Corporation (CTSO)

There are three common ways to get CTSO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CTSO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CTSO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Cytosorbents Corporation (CTSO)

CTSO is a real, high-margin device business priced like a distressed one. The November 2026 financing bought time on the Avenue loan, now due July 2028, at the cost of more shares. The outcome turns on keeping its Nasdaq listing, holding cash breakeven and a DrugSorb-ATR resubmission planned for 2027.

More on Cytosorbents Corporation (CTSO)

Whether CTSO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CTSO a buy or a sell?, and where the stock could go from here in the CTSO stock forecast.

For income investors, whether CTSO pays a dividend and how the payout looks is covered in does CTSO pay a dividend? And to weigh CTSO against a peer, read the full side-by-side comparisons: CTSO vs BAX and CTSO vs ATR.

Wondering how CTSO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Cytosorbents Corporation

Ask Walnut's AI anything about CTSO and see how it fits what you own.

FAQ

What does CytoSorbents do?

+

CytoSorbents develops and sells blood purification cartridges filled with porous polymer beads. When blood passes through the cartridge, the beads capture molecules in a certain size range, including inflammatory cytokines, bilirubin, myoglobin and some drugs. The flagship product, CytoSorb, has European Union approval and is used in intensive care for conditions such as septic shock and in cardiac surgery during bypass. The company is based in Princeton, New Jersey, manufactures there and runs its main European subsidiary in Berlin, Germany. Its pipeline includes DrugSorb-ATR, which targets blood thinner removal during urgent heart surgery, and HemoDefend-BGA, which aims to make universal plasma and platelets. Almost all sales are outside the United States, where the company sold only about $70,000 of product in the third quarter of 2026.

Why did the CTSO share price change so much in 2026?

+

The price on screens jumped because of the 1-for-20 reverse stock split that took effect on September 8, 2026, which turned every 20 shares into one and cut the share count from ~63 million to ~3.15 million. The split was done to restore compliance with Nasdaq's $1.00 minimum bid rule, which the company regained on September 23. On a split-adjusted basis the stock has ranged from ~$2.84 to ~$17.00 over the past year and closed at ~$4.39 on November 20, 2026, giving a market value of about ~$14 million before the new offering shares. The underlying pressure came from the FDA's 2025 decision on DrugSorb-ATR, flat revenue, a going-concern warning and the debt due in 2027. Daily trading volume is thin, often tens of thousands of shares, so moves of several percent in a day are common.

Is CytoSorbents profitable?

+

No. The company has lost money every year, with net losses of ~$20.7 million in 2024 and ~$8.2 million in 2025. For the first nine months of 2026 the net loss was ~$12.0 million, or ~$3.82 per share, though ~$2.5 million of that was a non-cash currency loss and ~$2.6 million was interest. The operating loss is narrowing quickly: it was ~$1.2 million in Q3 2026 versus ~$2.9 million a year earlier, and adjusted EBITDA loss shrank to ~$0.3 million. The company reported roughly breakeven operating cash flow in Q3 excluding restructuring payments. Gross margin of ~75% is high for a device maker, so profitability depends mostly on sales growth and on interest costs once the debt is dealt with.

How did CytoSorbents do in its latest quarter?

+

In the third quarter of 2026, reported November 12, revenue was ~$9.73 million, up ~2.6% from a year earlier and up from ~$9.63 million in Q2. Net loss narrowed to ~$1.83 million from ~$4.42 million in the prior quarter, and the per-share loss of ~-$0.58 was smaller than the ~-$0.90 analysts expected. Gross margin rose to ~75% and operating cash flow was roughly breakeven excluding restructuring payments. Analysts expect ~$9.63 million of revenue in the fourth quarter.

How has CTSO stock performed in 2026?

+

Poorly. As of November 20, 2026 the stock closed at ~$4.39, down ~66.5% year to date and ~64.7% over the past year on a split-adjusted basis, with a 52-week range of ~$2.84 to ~$17.00. It fell ~38% over the last three months and ~17% over the last month, including the period around the November 2026 financing priced at $4.94 a share. The two analysts tracked by Yahoo Finance rate it a hold.

What is the going-concern warning about?

+

In its third-quarter 10-Q the company stated that its cash position, expected cash use and the terms of its amended Avenue Capital loan raise substantial doubt about its ability to continue as a going concern for twelve months. At September 30, 2026 it had ~$5.7 million of cash, of which ~$1.5 million was restricted, against ~$17.5 million of debt classified as current. Under the amended loan, interest-only payments end December 31, 2026, and the balance amortizes monthly until it is due on July 1, 2027. The company lists options including new debt, government grants, royalty financing, asset sales or licensing, and equity offerings under its shelf registration. It also says it could slow expansion, delay regulatory work or cut headcount further if money is not available. On November 20, 2026 it announced a ~$4.0 million share offering and a third loan amendment that cut principal to ~$12.25 million, extended interest-only payments to March 31, 2028 and moved maturity to July 1, 2028.

What happened with DrugSorb-ATR at the FDA?

+

DrugSorb-ATR was submitted to the FDA as a De Novo device to reduce bleeding in patients undergoing coronary bypass surgery while still on Brilinta. The main STAR-T trial missed its primary effectiveness endpoint, announced in December 2023, though the company pointed to benefits in subgroups. The FDA denied the application and, in August 2025, upheld the denial on appeal while noting no device safety concerns. It asked for more real-world evidence. CytoSorbents now plans a new De Novo filing in early 2027 that adds an independent 587-patient analysis and an animal study, increasing treated patients in the submission to about 250. A separate filing for Eliquis and Xarelto removal is also planned. No approval has been granted, and the timing depends on FDA protocol sign-off.

Could CTSO be delisted from Nasdaq?

+

It is possible. In July 2026 Nasdaq notified the company that the market value of its listed securities was below the $35 million minimum for the Nasdaq Capital Market. The company has until December 28, 2026 to keep its market value at or above $35 million for ten straight business days, which at ~3.15 million shares implied a price above ~$11 before the November 2026 offering; the added shares lower that threshold somewhat. An alternative route is showing stockholders' equity of at least $2.5 million, but equity was a deficit of ~$2.3 million at September 30; the November share issuance and the stock repayment of ~$2.25 million of debt both add to equity, and the next balance sheet will show where it lands. If neither happens, Nasdaq would send a delisting notice, and the company could appeal to a hearings panel, which often grants extra time. The minimum bid issue was resolved by the September reverse split.

How much of the business depends on Germany?

+

Germany has been the company's largest single market because CytoSorb gained early adoption in German intensive care units and cardiac surgery centers. That dependence is falling. Product sales in Germany were ~31% of revenue in Q3 2025 and ~23% in Q3 2026, with German sales down ~21% year over year after the company shrank its direct sales force there. Over nine months, Germany was ~26% of revenue versus ~33% a year earlier. Distributor and partner territories, including Italy, India and countries across Europe, Latin America, the Middle East and Southeast Asia, now account for roughly half of sales. Management has started rebuilding German coverage, so the next few quarters will show whether that market stabilizes.

How can someone invest in CTSO?

+

CTSO trades on the Nasdaq Capital Market, so any U.S. brokerage that offers Nasdaq stocks can place an order, and many offer fractional shares. Because daily volume is low, often tens of thousands of shares, limit orders give more control over the fill price than market orders. The company pays no dividend and has an accumulated deficit of ~$324 million, so returns depend entirely on the share price. Anyone looking at it is weighing a business with ~$37 million of high-margin sales against a debt maturity now pushed to July 2028, a going-concern warning, the chance of dilutive financing and a possible delisting. Walnut can show how a small position like this compares with the rest of a portfolio, and it is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Cytosorbents Corporation's investor relations page or your broker before making investment decisions.